Member Login
  1. Stocks
    2. /
  2. Bausch Health Companies Inc. (NYSE: BHC)
    3. /

NYSE:BHC (Bausch Health Companies Inc.)

About BHC

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.
Financial Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Bausch Health Companies Inc. (NYSE: BHC) Latest News

    The Motley Fool
    Investing

    Is Valeant Pharmaceuticals Intl Inc. Still a Good Buy?

    | Demetris Afxentiou

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has been in the cross hairs of the media recently, and the stock has tanked…

    Read more »

    The Motley Fool
    Investing

    Why Did Concordia Healthcare Corp. Shares Fall 50%?

    | Benjamin Sinclair

    Concordia Healthcare Corp. (TSX:CXR)(NYSE:CXRX) shares have fallen by 50% since September 8th. Is this the opportunity of a lifetime?

    Read more »

    The Motley Fool
    Investing

    These 2 Oversold Healthcare Stocks Are too Cheap to Ignore Any Longer

    | Joseph Solitro

    Concordia Healthcare Corp. (TSX:CXR)(NASDAQ:CXRX) and Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) are oversold and could generate huge returns going forward. Which…

    Read more »

    The Motley Fool
    Investing

    Are Valeant Pharmaceuticals Intl Inc. and Concordia Healthcare Corp. Bargains After Crashing?

    | Benjamin Sinclair

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) and Concordia Healthcare Corp. (TSX:CXR)(NYSE:CXRX) have seen their share prices absolutely plunge.

    Read more »

    The Motley Fool
    Investing

    Is Valeant Pharmaceuticals Intl Inc.’s 34% Decline an Opportunity to Buy?

    | Kay Ng

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has fallen 34% in two months. Is the high-growth pharmaceutical company a bargain or should…

    Read more »

    The Motley Fool
    Investing

    Concordia Healthcare Corp. and Valeant Pharmaceuticals Intl Inc. Suffer Big Declines

    | Karen Thomas, MSc, CFA

    The Democrats have their eyes on limiting drug-price increases. It's good for patients, but not so much for Valeant Pharmaceuticals…

    Read more »

    The Motley Fool
    Investing

    4 Dirty Secrets Bay Street Bankers Don’t Want You to Know

    | Nelson Smith

    Find out why you should be very wary of what Bay Street tells you, using Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX)…

    Read more »

    The Motley Fool
    Investing

    Should the Recession News Change Your Investing Strategy?

    | Adam Mancini

    The answer to Canada's recession is a properly diversified portfolio. This may mean reducing commodity names like Canadian Oil Sands…

    Read more »

    The Motley Fool
    Investing

    3 Growth Stocks for a Low-Growth Economy

    | Adam Mancini

    Canadian and global growth is slowing. Fortunately, you can still find growth in stocks like Agrium Inc. (TSX:AGU)(NYSE:AGU), CGI Group…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. Continues to Impress With Another Acquisition

    | Demetris Afxentiou

    While the market is experiencing a downturn period of slowness, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) continues to grow.

    Read more »

    The Motley Fool
    Investing

    Is Valeant Pharmaceuticals Intl Inc. a Buy on Recent Acquisition News?

    | Jacob Donnelly

    Buying Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) on its acquisition news is a smart investment because often when it buys new…

    Read more »

    The Motley Fool
    Dividend Stocks

    Steal These 3 Investing Tips From 1 of Canada’s Best Investors

    | Nelson Smith

    There are many lessons to be learned from Stephen Jarislowsky, one of Canada's greatest investors. Here's why he'd avoid Valeant…

    Read more »